)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Telix Pharmaceuticals
Telix Pharmaceuticals (TLX) investor relations material
Telix Pharmaceuticals Q3 2026 TU earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 TU earnings summary20 Oct, 2026
Executive summary
Q3 2026 revenue reached US$245M, up 19% YoY; strong September sales supported a higher exit rate and demand for PSMA imaging products.
FDA approval of Pixclara added the first U.S.-approved imaging agent for glioma; BiPASS completed enrollment and received FDA Fast Track Designation.
FY 2026 revenue and other income are expected to exceed US$1B, with revenue tracking toward the upper end of guidance.
Financial highlights
Group revenue was US$245M versus US$206M in Q3 2025, up 19% YoY and down 1% QoQ.
Precision Medicine revenue was US$201M versus US$155M, up 30% YoY and flat QoQ.
TMS third-party revenue was US$44M versus US$47M, down 6% YoY and 2% QoQ.
Outlook and guidance
FY 2026 revenue and other income expected to exceed US$1B; revenue is tracking toward the upper end of US$950M–US$970M guidance, plus US$40M other income.
Revenue guidance includes a full-year RLS contribution and anticipated Pixclara sales in markets with marketing authorization.
FY 2026 R&D expenditure guidance revised to US$240M–US$260M from US$230M–US$270M, subject to planned clinical, regulatory and development milestones.
Management expects over 25% Precision Medicine revenue growth in 2026, supported by strong demand and September exit run rate.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Telix Pharmaceuticals
- Revenue rose 214%, turning FY2023 profitable as cash flow funded pipeline growth.TLX
H2 2023 - Late-stage pipeline, global expansion, and strategic deals drive radiopharma leadership.TLXR&D Day 2026
- US$1.65B merger creates a global radiopharma leader with EBITDA positivity targeted by 2027.TLXM&A announcement
- Imaging-driven growth funds late-stage trials in urology and neuro-oncology, with major data ahead.TLXH.C. Wainwright 28th Annual Global Investment Conference
- FDA approval, pipeline expansion, and integrated distribution drive radiopharma leadership.TLXMorgan Stanley 24th Annual Global Healthcare Conference
- Revenue up 22% to $477.3M, net profit $38.3M, margin and pipeline gains drive strong outlook.TLXH1 2026
- Q2 2026 revenue up 21% YoY to US $247M, with FY 2026 revenue expected to surpass US $1B.TLXQ2 2026 TU
- Revenue up 65% to $364M, net profit $29.7M, and $650M raised for future growth.TLXH1 2024
- Late-stage urology and pan-cancer assets advance, expanding the pipeline with novel radiopharmaceuticals.TLXStatus Update
Next Telix Pharmaceuticals earnings date
Investor Day 20263 Nov, 2026
Telix Pharmaceuticals
Next Telix Pharmaceuticals earnings date
Investor Day 20263 Nov, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Telix Pharmaceuticals Limited is a global biopharmaceutical company at the commercial stage, primarily engaged in developing diagnostic and therapeutic products using targeted radiation for cancer and rare diseases. The company is pioneering in the field of radiopharmaceuticals, aiming to advance precision medicine through its innovative approach. Telix's product development focuses on molecularly targeted radiation (MTR) products that seek to improve patient outcomes by precisely targeting diseased cells, thereby minimizing the impact on healthy tissues. Its research pipeline includes a range of diagnostic and therapeutic agents for conditions such as prostate cancer, kidney cancer, glioblastoma (brain cancer), and hematologic cancers, as well as bone marrow conditioning for rare diseases. TThe company is headquartered in North Melbourne, Australia, and its shares are listed on the ASX.